You are now leaving the United Therapeutics ASSIST website and moving to an external website independently operated and not managed by United Therapeutics, Inc.
If you do not wish to leave this site, click Cancel. Or click OK to continue.
Preferred Method of Contact *
*Indicates required field.
This Form is NOT intended to contact United Therapeutics Corporation’s Medical Information Department or to report suspected Adverse Events. In the event of either, please use the contact information below.
Medical Information: Call 1-877-522-2950 or send requests directly to: DrugInformation@unither.com. Adverse Events: To report a suspected adverse reaction (ADR) to United Therapeutics, please send ADR information to DrugSafety@unither.com, or by faxing the ADR information to 1-919-313-1297, or to report ADRs to the FDA, ADR information can be submitted at 1-800-FDA-1088 or www.fda.gov/medwatch.
Thank you for your interest.
We will be in contact with you soon in regard to this inquiry.
Thank you for your interest in prescribing Remodulin® (treprostinil) injection. This referral form has recently been revised to include the Remunity® Pump for Remodulin, a new subcutaneous delivery pump option for your patients.
United Therapeutics is committed to ensuring the best experience for you and your patients through education and support. To learn more about the pump and considerations prior to prescribing, please request additional information or a visit from a representative using the form below.
Thank you, your request has been received. Please click below to continue to the PDF download.
iAssist allows healthcare providers (HCPs) to submit electronic prescriptions and referral forms, perform advanced benefit verifications, submit real-time electronic prior authorizations, obtain patient electronic consent, and track patient adherence to therapy through portal notifications.
Currently, the 48 mcg (112 ct) and 64 mcg (112 ct) Maintenance Kits (28-day supply) are available for ordering. These strengths correspond with 8-10 breaths and 11-12 breaths with the TYVASO nebulizer, respectively. The remaining Maintenance Kits and Titration Kits will be available soon.
To learn more about TYVASO DPI and Kit availability, please reach out to your local United Therapeutics Cardiopulmonary Specialist.
Pulmonary Hypertension Association is a worldwide community of patients, caregivers, family members, and healthcare professionals whose mission is to extend and improve the lives of people with PAH.
PH Aware works for awareness and global engagement on behalf of families, caregivers, and healthcare professionals, and supports research efforts to find a cure for PAH.
The Scleroderma Foundation's three-fold mission is to provide support, education, and research. The foundation has 19 active chapters and 160 support groups across the country.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
Warnings and Precautions
For additional information please see Full Prescribing Information or call Customer Service at 1-877-UNITHER (1-877-864-8437)
All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.
© 2022 United Therapeutics Corporation. All rights reserved.